An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday. The positive results mean a potentially life-extending treatment is one step closer to being available on the market. They also herald a significant and...
An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday. The positive results mean a potentially life-extending treatment is one step closer to being available on the market. They also herald a significant and...
<iframe src="https://statesidedaily.com/embed/cluster/e358cb4bca79ee6c490bf46b857c4c03e3c125c4" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Moderna, Merck mRNA cancer vaccine prevents melanoma from returning"></iframe>
